Marty VN, Farokhnia M, Munier JJ, Mulpuri Y, Leggio L, Spigelman I
Some GLP-1 medications have demonstrated cardiovascular protective effects in specific populationsliraglutide, semaglutide injection, and dulaglutide have shown cardiovascular outcome benefits, with Wegovy (semaglutide) recently receiving an FDA indication for cardiovascular risk reduction in adults with established cardiovascular disease and either overweight or obesity
1 Make sure to review your medications with your healthcare provider before taking a semaglutide (GLP-1 RA)
This means early use of GLP-1 and SGLT2 inhibitors, especially in patients with established cardiovascular disease
The same physiology that drives these benefits, particularly delayed gastric emptying, also explains many of the complications seen in the ED
This means these medications promote feelings of fullness by mimicking the hormone that regulates hunger signals from the brain